Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enapotamab vedotin - Genmab

Drug Profile

Enapotamab vedotin - Genmab

Alternative Names: AXL-107-MMAE; HuMax-AXL; HuMax®-AXL-ADC

Latest Information Update: 15 Dec 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 14 Dec 2023 Seagen has been acquired by Pfizer
  • 12 Nov 2021 Genmab completes a phase-I/II trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom, Belgium, USA, Netherlands, Denmark and Spain(Parenteral) (NCT02988817)
  • 24 Nov 2020 Discontinued - Phase-II for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom, Belgium, USA, Netherlands, Denmark (Parenteral) as data from expansion cohorts did not meet stringent criteria for proof-of-concept

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top